<DOC>
	<DOCNO>NCT02300571</DOCNO>
	<brief_summary>This observational study propose observe effect high-dose , post-transplantation cyclophosphamide T cell-replete , HLA-matched PBSC graft HLA-identical mismatch donor .</brief_summary>
	<brief_title>Observational Study Combination Post-transplant High Dose Cyclophosphamide , Tacrolimus Mycophenolate Mofetil Prevention Acute Graft-versus-Host Disease Patients Eligible Allogeneic Hematopoietic Stem Cell Transplant</brief_title>
	<detailed_description>Allogeneic hematopoietic cell transplantation ( HCT ) remain curative approach many hematological malignancy . In allogeneic HCT donor immune system donor lymphocytes exerts beneficial detrimental effect . Graft versus host disease ( GVHD ) represent major complication cause mortality allogeneic HCT . The principal aim clinical transplant research must accomplish next year elaborate transplant strategy devoid GVHD still capable generate , donor lymphocyte , graft versus tumor effect ( GVT ) . The used GVHD prophylaxis regimen remain association calcineurin-inhibitor ( CNIs ) six month four low-doses methotrexate ( MTX ) long length prophylaxis impact process post-transplant immune reconstitution slow expose patient high risk develop severe infection . The use post-transplant cyclophosphamide look promise among new approach GVHD control . The study design observational retrospective/prospective Study Patients Eligible Allogeneic Hematopoietic Stem Cell Transplant use Peripheral Blood Stem Cells ( PBSC ) unrelated related , HLA-identical partially mismatch donor . In case unrelated donor , donor selection do accordingly Italian Bone Marrow Donor Registry ( IBMDR ) . This protocol treatment plan outline limited plan GVHD prevention . The treatment plan patient include pre-conditioning therapy , TBI/chemotherapy , central nervous system prophylaxis plan therapy , describe primary transplant protocol patient assign investigational site .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>1 . Patient schedule transplant 'mobilized ' peripheral blood stem cell ( PBSC ) genotypically HLAunrelated related identical partially mismatched stem cell donor . 2 . Patient ≥ 18 year ≤ 65 year age . 3 . Diagnosis malignancy . Patients divided basis disease low risk high risk patient . High risk disease : AML &gt; CR1 , ALL &gt; CR1 , CML CP # 2 , AP BP , nonHodgkin 's lymphoma &gt; CR2 , Hodgkin 's lymphoma &gt; CR2 , patient refractory malignancy Low risk : multiple myeloma ( patient ) , AML CR1 , myelodysplastic syndrome beyond RA ( include CMML ) ALL CR1 . 4 . Patient legal guardian signed/dated informed consent form . 5 . Female patient must negative pregnancy test ( blood urine ) unless prepuberal surgically sterile . 6 . Estimated Creatinine Clearance ≥ 60 mL/min time consent . 7 . Total bilirubin ≤ 1.5 time upper limit normal time consent . 8 . SGOT SGPT ≤ 2.0 time upper limit normal time consent . 1 . Patient &gt; 65 year age 2 . Patient signed/dated informed consent form . 3 . Patient receive Tcell deplete hematopoietic stem cell graft . 4 . Pregnant lactate woman 5 . Patient acute pulmonary infection suspect basis abnormal chest xray . 6 . Patient active systemic infection control antimicrobial therapy . 7 . Patient know carrier Human Immune Deficiency Viruses ( HIV1 others ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>